NHS England Backs Biosimilar-To-Biosimilar Switching As It Counts Adalimumab Savings

 
• By Aidan Fry
  
Arrows
Multiple switches between biosimilars do not raise safety concerns. NHS England has stated in a briefing document on adalimumab • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products